Diketoacid inhibitors of HIV-1 integrase: From L-708,906 to raltegravir and beyond

Current Medicinal Chemistry

Volumn 19, Issue 8, 2012, Pages 1177-1192

  Beare, K D ^a   Coster, M J ^b   Rutledge, P J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

AIDS; Antiretroviral drugs; Diketoacid; DKA; Elvitegravir; HIV; HIV 1 integrase; Integramycin; Integrase inhibitors; Raltegravir; SAR

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ANTIRETROVIRUS AGENT; DOLUTEGRAVIR; ELVITEGRAVIR; GSK 364735; INTEGRASE INHIBITOR; L 708906; MK 2048; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; OXOACID; RALTEGRAVIR; UNCLASSIFIED DRUG;

CROSS RESISTANCE; DRUG APPROVAL; DRUG SCREENING; ENZYME INHIBITION; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS STRAIN;

ACETOACETATES; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRROLIDINONES;

EID: 84858256291     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320565     Document Type: Review

References (134)

1. Weisman, J.; Gottlieb, M. S., Pneumocystis Pneumonia - Los Angeles. MMWR, 1981, 30, 250-252.
2. (a) Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M., Isolation of human T-cell leukaemia virus in acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 865-867;
3. (b) Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L., Isolation of a T-lymphotropic retrovirus from a patient at risk of aquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-870.
4. (a) UNAIDS/WHO AIDS 2008 Report of the Global AIDS Epidemic 2008. http://data.unaids.org/pub/EpiReport/2008/2008-EpiUpdate-en.pdf (accessed 14/9/2009);
5. UNAIDS fact sheet: Global Facts and Figures. http://data.unaids.org/pub/ FactSheet/2009/20091124-FS-global-en.pdf (accessed 5/09/2010).
6. Pommier, Y.; Johnson, A.; Marchand, C., Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery, 2005, 4, 236-248. (Pubitemid 40372557)
7. Richman, D., HIV chemotherapy. Nature, 2001, 410, 995-1001. (Pubitemid 32335851)
8. (a) De Clercq, E., New approaches toward anti-HIV chemotherapy. J. Med. Chem., 2005, 48(5), 1297-1313;
9. (b) Abel, S.; Back, D. J.; Vourvahis, M., Maraviroc: pharmacokinetics and drug interactions. Antivir. Ther., 2009, 14(5), 607-618.
10. (a) Hirsch, M. S., HIV drug resistance - a chink in the armor. N. Engl. J. Med., 2002, 347(6), 438-439;
11. (b) Johnson, A.; Marchand, C.; Pommier, Y., HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trials. Curr. Top. Med. Chem., 2003, 4(10), 1059-1077.
12. (a) Miller, M.; Witmer, M.; Stillmock, K.; Felock, P.; Ecto, L.; Flynn, J.; Schleif, W.; Dornadula, G.; Danovich, R.; Hazuda, D., Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. In XVI International AIDS Conference, Toronto, Canada, 2006;
13. (b) Serrao, E.; Odde, S.; Ramkumar, K.; Neamati, N., Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology, 2009, 6, 25.
14. Young, S. D.; Egbertson, M.; Pearson, P. G.; Wai, J.; Fisher, T.; Guare, J.; Embrey, M.; Tran, L.; Zhuang, L.; Vacca, J.; Langford, M.; Melamed, J.; Clark, D. L.; Medina, J. C.; Jaen, J. Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid derivatives useful as HIV integrase inhibitors. MERCK & Co. WO. 9962520, December 9, 1999.
15. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr., Coumarin-based inhibitors of HIV integrase. J. Med. Chem., 1997, 40(2), 242-249.
16. Pannecouque, C.; Pluymers, W.; Van Maele, B.; Tetz, V.; Cherepanov, P.; De Clercq, E.; Witrouw, M.; Debyser, Z., A new class of HIV integrase inhibitors that block viral replication in cell cultures. Curr. Biol., 2002, 12(14), 1169-1177. (Pubitemid 34801164)
17. Mouscadet, J. F.; Desmaele, D., Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules, 2010, 15(5), 3048-3078.
18. (a) Hazuda, D.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.; Espeseth, A.; Gabryelski, L.; Schelf, W.; Blau, C.; Miller, M., Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287, 646-650;
19. (b) Witrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs, Y.; Debyser, Z., Identification of authentic inhibitors of HIV-1 integration. Curr. Med. Chem.: Anti-Infect. Agents, 2005, 4(2), 153-165. (Pubitemid 40439599)
20. (a) Dayam, R.; Neamati, N., Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr. Pharm. Des., 2003, 9(22), 1789-1802;
21. (b) Dayam, R.; Deng, J.; Neamati, N., HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev., 2006, 26(3), 271-309;
22. (c) Dayam, R.; Rambabu, G.; Al-Mawsawi, L.; Neamati, N., HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev., 2008, 28(1), 118-154;
23. (d) Neamati, N., Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin. Ther. Patents 2002, 12(5), 709-724;
24. (e) Makhija, M. T., Designing HIV integrase inhibitors - shooting the last arrow. Curr. Med. Chem., 2006, 13(20), 2429-2441;
25. (f) Ramkumar, K.; Serrao, E.; Odde, S.; Neamati, N., HIV-1 integrase inhibitors: 2007-2008 update. Med. Res. Rev., 2010, 30(6), 890-954.
26. Al-Mawsawi, L.; Neamati, N., Allosteric inhibitor development targeting HIV-1 integrase. Chem. Med. Chem., 2011, 6(2), 228-241.
27. Abbas, A.; Litchman, A., Cellular and Molecular Immunology. 5th ed.; Saunders: Philadelphia, 2003; p 464-476.
28. (a) Maertens, G. N.; Cherepanov, P.; Pluymers, W.; Busschots, K.; De Clercq, E.; Debyser, Z.; Englelborghs, Y., LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem., 2003, 278(35), 33528-33539;
29. (b) Turlure, F.; Devroe, E.; Silver, P. A.; Engelman, A., Human cell proteins and human immunodeficiency virus DNA integration. Front. Biosci., 2004, 9, 3187-3208;
30. (c) Cherepanov, P.; Sun, Z.-Y. J.; Rahman, S.; Maertens, G. N.; Wagner, G.; Engelman, A., Solution structure of the HIV-1 integrase binding domain in LEDGF/p75. Nat. Struct. Biol., 2005, 12, 526-532. (Pubitemid 43085883)
31. Llano, M.; Delgado, S.; Vanegas, M.; Poeschla, E. M., Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem., 2004, 279(53), 55570-55577. (Pubitemid 40066560)
32. Parrill, A., HIV-1 integrase inhibition: binding sites, SARs and future perspectives. Curr. Med. Chem., 2003, 10(18), 1811-1824. (Pubitemid 37038602)
33. Hare, S.; Gupta, S. S.; Valkov, E.; Englelman, A.; Cherepanov, P., Retroviral intasome assembly and inhibition of DNA strand transfer. Nature, 2010, 464, 167-168.
34. Craigie, R., HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem., 2001, 276(26), 23213-23216.
35. Kulkosky, J.; Jones, K. S.; Katz, R. A.; Mack, J. P.; Skalka, A. M., Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell. Biol., 1992, 12(5), 2331-2338.
36. Goldgur, Y.; Craigie, R.; Cohen, G.; Fujiwara, T.; Yoshinaga, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D., Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor. Proc. Natl. Acad. Sci., 1999, 96(23), 13040-13043.
37. Lodi, P.; Ernst, J.; Kuszewski, J.; Hickman, A.; Engelman, A.; Craigie, R., Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry, 1995, 34(31), 9826-9833.
38. (a) Cai, M.; Zheng, R.; Caffrey, M.; Craigie, R.; Clore, G. M.; Gronenborn, A. M., Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol., 1997, 4, 567-577;
39. (b) Wang, J. Y.; Ling, H.; Yang, W.; Craigie, R., Structure of a two-domain fragment of HIV-1 integrase: implications from domain organization in the intact protein. EMBO J., 2001, 20(24), 7333-7343;
40. (c) Goldgur, Y.; Hickman, A.; Jenkins, T.; Craigie, R.; Davis, D., Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci., 1998, 95(16), 9150-9154;
41. (d) Chen, J. C.; Krucinski, J.; Miercke, L. J.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M., Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci., 2000, 97(15), 8233-8238. (Pubitemid 30639655)
42. (a) Krishnan, L.; Li, X.; Naraharisetty, H. L.; Hare, S.; Cherepanov, P.; Engelman, A., Structure-based modelling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci., 2010, 107(36), 15910-15915;
43. (b) Maertens, G. N.; Hare, S.; Cherepanov, P., The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature, 2010, 468, 326-329.
44. (a) Godwin, C.; Pais, G.; Zhang, X.; Marchand, C.; Neamanti, N.; Cowansage, K.; Svarovskaia, E.; Pathak, V.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T., Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 inhibitors. J. Med. Chem., 2002, 45(15), 3184-3194;
45. (b) Grobler, J.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A.; Wolfe, A.; Esbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.; Young, S.; Vacca, J.; Hazuda, D., Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci., 2002, 99(10), 6661-6666. (Pubitemid 34526189)
46. Maignan, S.; Guilloteau, J. P.; Zhou-Lui, Q.; Clément-Mella, C.; Mikol, V., Crystal structure of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol., 1998, 282(2), 359-368. (Pubitemid 28418789)
47. Dyda, F.; Hickman, A.; Jenkins, T.; Englelman, A.; Craigie, R.; Davies, D., Crystal structure of the catalytic domain of HIV-1 integrase. Science, 1994, 266, 1981-1986.
48. Diamond, T. L.; Bushman, F. D., Role of metal ions in catalysis by HIV integrase analysed using quantitative PCR disintegration assay. Nucleic Acids Res., 2006, 34(21), 6116-6125. (Pubitemid 44942733)
49. Maurin, C.; Bailly, F.; Buisine, E.; Vezin, H.; Mbemba, G.; Mouscadet, J. F.; Cotelle, P., Spectroscopic studies of diketoacids-metal interactions. J. Med. Chem., 2004, 47(22), 5583-5586.
50. Engelman, A.; Mizuuchi, K.; Craigie, R., HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer. Cell, 1991, 67(6), 1211-1221. (Pubitemid 121001533)
51. Pemberton, I. K.; Buckle, M.; Buc, H., The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II). J. Biol. Chem., 1996, 271(3), 1498-1506. (Pubitemid 26028636)
52. Hare, S.; Vos, A. M.; Clayton, R. F.; Thuring, J. W.; Cummings, M. D.; Cherepanov, P., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci., 2010, 107(46), 20057-20062.
53. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L.; Neamati, N., From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by β-diketo acid metal complexes. J. Med. Chem., 2006, 49(14), 4248-4260. (Pubitemid 44036668)
54. Maurin, C.; Bailly, F.; Cotelle, P., Structure-activity relationships of HIV-1 integrase inhibitors - enzyme ligand interactions. Curr. Med. Chem., 2003, 10(18), 1795-1810. (Pubitemid 37038601)
55. Espeseth, A.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J.; Young, S.; Hamill, T.; Cole, J.; Hazuda, D., HIV-1 integrase inhibitors that compete with target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci., 2000, 97(21), 11244-11249.
56. Marchand, C.; Johnson, A.; Karki, R.; Pais, G.; Zhang, X.; Cowansage, K.; Patel, T.; Nicklaus, M.; Burke, T.; Pommier, Y., Metal-dependent inhibition of HIV-1 integrase by β-diketo acids. Mol. Pharmacol., 2003, 64(3), 600-609.
57. Pais, G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E.; Pathak, V.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T., Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1- integrase inhibitors. J. Med. Chem., 2002, 45(15), 3184-3194.
58. Walker, M.; Johnson, T.; Ma, Z.; Banville, J.; Remillard, R.; Kim, O.; Zhang, Y.; Staab, A.; Wong, H.; Torri, A.; Samanta, H.; Lin, Z.; Deminie, C.; Terry, B.; Krystal, M.; Meanwell, N., Triketoacid inhibitors of HIVintegrase: a new chemotype useful for probing the integrase pharmacophore. Bioorg. Med. Chem. Lett., 2006, 16(11), 2920-2924.
59. Pluymers, W.; Pais, G.; Van Maele, B.; Pannecouque, C.; Fikkert, V.; Burke, T.; De Clerq, E.; Witvrouw, M.; Neamati, N.; Debyser, Z., Inhibition of HIV-1 integration by diketo derivatives. Antimicrob. Agents Chemother., 2002, 46(10), 3292-3297.
60. Long, Y.; Jiang, X.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N., Rational design and synthesis of novel dimeric diketo-containing inhibitors. J. Med. Chem., 2004, 47(10), 2561-2573.
61. Chi, G.; Nair, V.; Semenova, E.; Pommier, Y., A novel diketo phosphonic acid that exhibits specific, strand transfer inhibition of HIV integrase and anti-HIV activity. Bioorg. Med. Chem. Lett., 2006, 17(5), 1266-1269. (Pubitemid 46240849)
62. Zeng, L.-F.; Jiang, X.-H.; Sanchez, T.; Zhang, H.-S.; Dayam, R.; Neamati, N.; Long, Y.-Q., Novel dimeric arylketo containing inhibitors of HIV-1 integrase: effects of the phenyl substituent and the linker on orientation. Bioorg. Med. Chem., 2008, 16(16), 7777-7787.
63. Costi, R.; Di Santo, R.; Arico, M.; Roux, A.; Ragno, R.; Massa, S.; Tramontano, E.; La Colla, M.; Loddo, R.; Marongiu, M.; Pani, A.; La Colla, P., 6-Aryl-2,4-dioxo-5-hexinoix acids, novel integrase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(7), 1745-1749.
64. Sechi, M.; Sannia, L.; Carta, F.; Palomba, M.; Dallocchio, R.; Dessi, A.; Derudas, M.; Zawahir, Z.; Neamati, N., Design of novel bioisosteres of β-diketo acid inhibitors of HIV-1 integrase. Antivir. Chem. Chemother., 2005, 16(1), 41-61. (Pubitemid 40754328)
65. Li, X.; Vince, R., Conformationally restrained carbazolone-containing α,γ-diketo acids as inhibitors of HIV integrase. Bioorg. Med. Chem., 2006, 14(9), 2942-2955.
66. Marchand, C.; Zhang, X.; Pais, G.; Cowansage, K.; Neamati, N.; Burke, T.; Pommier, Y., Structural determinants for HIV-1 integrase inhibition by β- diketo acids. J. Biol. Chem., 2002, 277(15), 12596-12603. (Pubitemid 34952618)
67. Walker, M.; Johnson, T.; Ma, Z.; Zhang, Y.; Banville, J.; Remillard, R.; Plamondon, S.; Pendri, A.; Wong, H.; Smith, D.; Torri, A.; Samanta, H.; Lin, Z.; Deminie, C.; Terry, B.; Krystal, M.; Meanwell, N., Exploration of the diketoacid integrase inhibitor chemotype. Bioorg. Med. Chem. Lett., 2006, 16(22), 5818-5821.
68. (a) Barreca, M. L.; Ferro, S.; Rao, A.; De Luca, L.; Zappala, M.; Monforte, A.-M.; Witvrouw, M.; Chimirri, A., Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem., 2005, 48(22), 7084-7088;
69. (b) De Luca, L.; Barreca, M. L.; Ferro, S.; Iraci, N.; Michiels, M.; Christ, F.; Debyser, Z.; Witvrouw, M.; Chimirri, A., A refined pharmacophore model for HIV-1 integrase inhibitors: optimisation of potency in the 1H benzylidole series. Bioorg. Med. Chem. Lett., 2008, 18(9), 2891-2895. (Pubitemid 351608882)
70. De Luca, L.; De Grazia, S.; Ferro, S.; Gitto, R.; Christ, F.; Debyser, Z.; Chimirri, A., HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modelling investigation. Eur. J. Med. Chem., 2010, 46(2), 756-764.
71. Wai, J.; Egbertson, M.; Payne, L.; Fisher, T.; Embrey, M.; Tran, L.; Melamed, J.; Langford, M.; Guare, J.; Zhuang, L.; Grey, V.; Vacca, J.; Holloway, M.; Naylor-Olsen, A.; Hazuda, D.; Felock, P.; Wolfe, A.; Stillmock, K.; Schelf, W.; Gabryelski, L.; Young, S., 4-Aryl-2,4- dioxobutanoic acid inhibitors of HIV-1 integrase. J. Med. Chem., 2000, 43(26), 4923-4926.
72. Zhang, X.; Pais, G.; Svarovskaia, E.; Marchand, C.; Johnson, A.; Karki, R.; Nicklaus, M.; Pathak, V.; Pommier, Y.; Burke, T., Azido-containing aryl β- diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(6), 1215-1219.
73. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W., Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol., 1994, 48(3), 595-608. (Pubitemid 24257024)
74. Maurin, C.; Bailly, F.; Mbemba, G.; Mouscadet, J. F.; Cotelle, P., Design, synthesis and anti-integrase activity of catechol-DKA hybrids. Bioorg. Med. Chem., 2006, 14(9), 2978-2984.
75. Nair, V.; Uchil, V.; Neamati, N., β-Diketo acids with purine nucleobase scaffolds: novel, selective inhibitors of the strand transfer step of HIV integrase. Bioorg. Med. Chem. Lett., 2006, 16(7), 1920-1923. (Pubitemid 43267377)
76. Nair, V.; Chi, G.; Ptak, R.; Neamati, N., HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. J. Med. Chem., 2006, 49(2), 445-447. (Pubitemid 43157474)
77. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C. M.; Nencioni, L.; Palamara, A. T.; Pommier, Y.; Marchand, C., Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 inhibitors:. J. Med. Chem., 2006, 49(6), 1939-1945.
78. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R., Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267(3), 727-748. (Pubitemid 27170693)
79. Dayam, R.; Neamati, N., Active site binding modes of the β-diketoacids. Bioorg. Med. Chem., 2004, 12(24), 6371-6381.
80. (a) Keseru, G. M.; Kolossvary, I., Fully flexible low-mode docking: Application to induced fit in HIV integrase. J. Am. Chem. Soc., 2001, 123(50), 12708-12709;
81. (b) Sotriffer, C. A.; Ni, H.; McCammon, A. J., HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc., 2000, 122(25), 6136-6137;
82. (c) Sotriffer, C. A.; Ni, H.; McCammon, A. J., Active site binding mode of HIV-1 integrase inhibitors. J. Med. Chem., 2000, 43(22), 4109-4117.
83. (a) Savarino, A., In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology, 2007, 4, 21;
84. (b) Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A., Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem, 2009, 4(9), 1446-1456.
85. Melek, M.; Jones, J.; O'Dea, M.; Pais, G.; Burke, T.; Pommier, Y.; Neamati, N.; Gellert, M., Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc. Natl. Acad. Sci., 2001, 99(1), 134-137.
86. Bilich, A., S-1360 (Shionogi-GlaxoSmithKline). Curr. Opin. Investig. Drugs, 2003, 4(2), 206-209.
87. (a) Fujishita, T.; Yoshinaga, T.; Sato, A. Preparation of aromatic heterocycle compounds having HIV integrase inhibiting activities. SHIONOGI & Co. WO. 0039086, July 6, 2000;
88. (b) Payne, L.; Tran, L.; Zhuang, L.; Young, S.; Egbertson, M.; Wai, J.; Embrey, M.; Fisher, T.; Guare, J.; Langford, M.; Melamed, J.; Clark, D. L. Preparation of 1,3-diaryl-1,3-propanediones as HIV integrase inhibitors. MERCK & Co. WO. 0100578, January 1, 2001.
89. Kawasuji, T.; Yoshinaga, T. Integrase inhibitors containing aromatic heterocycle derivatives. SHIONOGI & Co. WO. 0117968, March 15, 2001.
90. Zhuang, L.; Wai, J.; Embrey, M.; Fisher, T.; Egbertson, M.; Payne, L.; Guare, J.; Vacca, J.; Hazuda, D.; Felock, P.; Wolfe, A.; Stillmock, K.; Witmer, M.; Moyer, G.; Schleif, W.; Gabryelski, L.; Leonard, Y.; Lynch, J.; Michelson, S.; Young, S., Design and synthesis of 8-hydroxy-[1,6]-naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem., 2003, 46(4), 453-456. (Pubitemid 36182747)
91. Egbertson, M.; Melamed, J.; Langford, M.; Young, S. Hydroxynaphthyridinone carboximides useful as HIV integrase inhbitors. MERCK & Co. WO. 03062204, July 31, 2003.
92. Boros, E. E.; Johns, B. A.; Garvey, E. P.; Koble, C. S.; Miller, W. H., Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg. Med. Chem. Lett., 2006, 16(21), 5668-5672. (Pubitemid 44415431)
93. Wai, J.; Kim, B.; Fisher, T.; Zhuang, L.; Embrey, M.; Williams, P. D.; Staas, D. D.; Culberson, C.; Lyle, T. A.; Vacca, J.; Hazuda, D.; Felock, P.; Schelf, W.; Gabryelski, L.; Lixia, J.; Chen, I.-W.; Ellis, J. D.; Mallai, R.; Young, S., Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(20), 5595-5599. (Pubitemid 47391321)
94. Fardis, M.; Jin, H.; Jabri, S.; Cai, R. Z.; Mish, M.; Tsiang, M.; Kim, C. U., Effect of substitution on novel tricylic HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(15), 4031-4035. (Pubitemid 43922410)
95. (a) Jin, H.; Cai, R. Z.; Schacherer, L.; Jabri, S.; Tsiang, M.; Fardis, M.; Chen, X.; Chen, J. M.; Kim, C. U., Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(15), 3989-3992;
96. (b) Jin, H.; Wright, M.; Pastor, R.; Mish, M.; Metobo, S.; Jabri, S.; Lansdown, R.; Cai, R.; Pyun, P.; Tsiang, M.; Chen, X.; Kim, C. U., Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Bioorg. Med. Chem. Lett., 2008, 18(4), 1388-1391. (Pubitemid 351226542)
97. Li, X.; Vince, R., Synthesis and biological evaluation of purine derivatives incorporating metal chelating ligands as HIV integrase inhibitors. Bioorg. Med. Chem., 2006, 14(16), 5742-5755.
98. Kehlenbeck, S.; Betz, U.; Birkmann, A.; Fast, B.; Goller, A. H.; Henninger, K.; Lowinger, T.; Marrero, D.; Paessens, A.; Paulsen, D.; Pevzner, V.; Schohe-Loop, R.; Tsujishita, H.; Welker, R.; Kreuter, J.; Rubsamen- Waigmann, H.; Dittmer, F., Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase. J. Virol., 2006, 80(14), 6883-6894.
99. (a) Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Gonzalez Paz, O.; Laufer, R.; Monteagudo, E.; Pace, P., 3,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem., 2006, 49(23), 6646-6649;
100. (b) Pace, P.; Francesco, E. D.; Gardelli, C.; Harper, S.; Muraglia, E.; Nizi, E.; Orvieto, F.; Petrocchi, A.; Poma, M.; Rowley, M.; Scarpelli, R.; Laufer, R.; Gonzalez Paz, O.; Monteagudo, E.; Bonelli, F.; Hazuda, D.; Stillmock, K.; Summa, V., Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J. Med. Chem., 2007, 50(9), 2225-2239. (Pubitemid 46683075)
101. Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.; Ferrara, M.; Orvieto, F.; Pace, P.; Pescatorw, G.; Poma, M.; Ferreira, M.; Scarpelli, R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Gonzalez Paz, O.; Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K.; Hazuda, D.; Rowley, M.; Summa, V., Discovery and synthesis of HIV integrase inhibitors: Development of potent and orally bioavailable N-methylpyrimidones. J. Med. Chem., 2007, 50(20), 4953-4975. (Pubitemid 47525478)
102. Gatell, J. M.; Katlama, C.; Grinsztejn, B.; Eron, J. J.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C. J.; Danovich, R.; Wan, H.; Zhao, J.; Meibohm, A. R.; Strohmaier, K. M.; Harvey, C. M.; Isaacs, R. D.; Nguyen, B. Y., Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J. Acq. Immune Defic. Syndr., 2010, 53(4), 456-463.
103. Lennox, J. L.; Dejesus, E.; Berger, D. S.; Lazzarin, A.; Pollard, R. B.; Ramalho Madruga, J. V.; Zhao, J.; Wan, H.; Gilbert, C. L.; Teppler, H.; Rodgers, A. J.; Barnard, R. J.; Miller, M.; Dinubile, M. J.; Nguyen, B. Y.; Leavitt, R.; Sklar, P., Raltegravir versus efavirenz regimens in treatmentnaive HIV-1-infected patients: 96-Week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acq. Immune Defic. Syndr., 2010, 55(1), 39-48.
104. (a) Deeks, S. G.; Kar, S.; Gubernick, S. I.; Kirkpatrick, P., Raltegravir. Nat. Rev. Drug Discovery, 2008, 7, 117-118;
105. (b) Temesgen, Z.; Siraj, D. S., Raltegravir: first in class HIV integrase inhibitor. Ther. Clin. Risk Manag., 2008, 4(2), 494-500.
106. Muraglia, E.; Kinzel, O.; Gardelli, C.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Nizi, E.; Orvieto, F.; Pescatore, G.; Laufer, R.; Gonzalez Paz, O.; Di Marco, A.; Fiore, F.; Monteagudo, E.; Fonsi, M.; Felock, P.; Rowley, M.; Summa, V., Design and Synthesis of bicyclic pyrimidones as potent and orally bioavailable HIV-1 integrase inhbitors. J. Med. Chem., 2008, 51(4), 861-874. (Pubitemid 351304695)
107. Francesco, E. D.; Pace, P.; Fiore, F.; Naimo, F.; Bonelli, F.; Rowley, M.; Summa, V., Development of 2-t-butyl-N-methyl pyrimidones as potent inhibitors of HIV integrase. Bioorg. Med. Chem. Lett., 2008, 18(8), 2709-2713. (Pubitemid 351503872)
108. Sorbera, L. A.; Serradell, N., GS-9137: Anti-HIV agent HIV integrase inhibitor. Drugs of the Future, 2006, 31(4), 310-313.
109. Mascolini, M. In Merck offers unique perspective on second generation integrase inhibitor, 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 15-17; Amsterdam, 2009.
110. Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T., The naphthyridinone GSK-364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother., 2008, 52(3), 901-908. (Pubitemid 351358368)
111. Vandeckerckhove, L., GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr. Opin. Invest. Drugs, 2010, 11(2), 203-212.
112. Jones, E. A.; Vandergraaf, N.; Le, G.; Choi, N.; Issa, W.; Macfarlane, K.; Thienthong, N.; Winfield, L. J.; Coates, J. A. V.; Lu, L.; Li, X.; Feng, X.; Yu, C.; Rhodes, D. I.; Deadman, J. J., Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold. Bioorg. Med. Chem. Lett., 2010, 20(19), 5913-5917.
113. (a) Le, G.; Vandergraaf, N.; Rhodes, D. I.; Jones, E. R. H.; Coates, J. A. V.; Thienthong, N.; Winfield, L. J.; Lu, L.; Li, X.; Yu, C.; Feng, X.; Deadman, J. J., Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: Azoles: Effective metal chelators. Bioorg. Med. Chem. Lett., 2010, 20(19), 5909-5912;
114. (b) Le, G.; Vandergraaf, N.; Rhodes, D. I.; Jones, E. D.; Coates, J. A. V.; Lu, L.; Li, X.; Yu, C.; Feng, X.; Deadman, J. J., Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses. Bioorg. Med. Chem. Lett., 2010, 20(17), 5013-5018.
115. Newman, D. J., Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J. Med. Chem., 2008, 51(9), 2589-2599. (Pubitemid 351620778)
116. (a) Singh, S.; Jayasuriya, H.; Dewey, R.; Polishook, J. D.; Dombrowski, A. W.; Zink, D.; Guan, Z.; Collado, J.; Platas, G.; Pelaez, F.; Felock, P.; Hazuda, D., Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. J. Ind. Microbiol. Biotechnol., 2003, 30(12), 721-731;
117. (b) Singh, S.; Zink, D.; Heimbach, B.; Glenilloud, O.; Teran, A.; Silverman, K.; Lingham, R.; Felock, P.; Hazuda, D., Structure, stereochemistry and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org. Lett., 2002, 4(7), 1123-1126.
118. Tang, J.; Maddali, K.; Metifiot, M.; Sham, Y. Y.; Vince, R.; Pommier, Y.; Wang, Z., 3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase. J. Med. Chem., 2011, 54(7), 2282-2292.
119. Tang, J.; Maddali, K.; Pommier, Y.; Sham, Y.; Wang, Z., Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. Bioorg. Med. Chem. Lett., 2010, 20(11), 3275-3279.
120. Métifiot, M.; Marchand, C.; Maddali, K.; Pommier, Y., Resistance to integrase inhibitors. Viruses, 2010, 2(7), 1347-1366.
121. Hazuda, D.; Anthony, N.; Gomez, R. P.; Jolly, S. M.; Wai, J.; Zhuang, L.; Fisher, T.; Embrey, M.; Guare, J.; Egbertson, M.; Vacca, J.; Huff, J. R.; Felock, P.; Witmer, M.; Stillmock, K.; Danovich, R.; Grobler, J.; Miller, M.; Espeseth, A.; Jin, L.; Chen, I.-W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D., A naphthyridine carboxamide proved evidence for discordant resistance between inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci., 2004, 101(31), 11233-11238. (Pubitemid 39038330)
122. Fransen, S.; Grupta, S.; Danovich, R.; Hazuda, D.; Miller, M.; Witmer, M.; Petropoulos, C. J.; Huang, W., Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple non-overlapping genetic pathways. J. Virol., 2009, 83(22), 11440-11446.
123. (a) Cooper, D. A.; Steigbigel, R. T.; Gatell, J. M.; Rockstroh, J. K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P. N.; Eron, J. E.; Schechter, M.; Markowitz, M.; Loutfy, M. R.; Lennox, J. L.; Zhao, J.; Chen, J.; Ryan, D. M.; Rhodes, R. R.; Killar, J. A.; Gilde, L. R.; Strohmaier, K. M.; Meibohm, A. R.; Miller, M. D.; Hazuda, D.; Nessly, M. L.; DeNubile, M. J.; Isaacs, R. D.; Teppler, H.; Nguyen, B. Y., Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N. Engl. J. Med., 2008, 359(4), 355-365;
124. (b) Reigadas, S.; Anies, G.; Masquilier, B.; Calmels, C.; Stuyver, L. J.; Parissi, V.; Fleury, H.; Andreola, M.-L., The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS One, 2010, 5(4), e10311;
125. (c) Reigadas, S.; Masquilier, B.; Calmels, C.; Laguerre, M.; Lazaro, E.; Vandenhende, M.; Neau, D.; Fleury, H.; Andreola, M.-L., Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob. Agents Chemother., 2011, 55(7), 3187-3194.
126. (a) Hazuda, D.; Young, S.; Guare, J.; Anthony, N.; Gomez, R. P.; Wai, J.; Vacca, J.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R.; Witmer, M.; Wilson, K. A.; Tussey, L.; Schleif, W.; Gabryelski, L.; Jin, L.; Miller, M.; Casimiro, D. R.; Emini, E.; Shiver, J. W., Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science, 2004, 305, 528-532;
127. (b) Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuko, M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol., 2008, 82(2), 764-774.
128. Metifiot, M.; Vandergraaf, N.; Maddali, K.; Naumova, A.; Zhang, X.; Rhodes, D. I.; Marchand, C.; Pommier, Y., Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS, 2011, 25(9), 1175-1178.
129. Bar-Magen, T.; Sloane, R. D.; Donahue, D. A.; Kuhl, B. D.; Zabeida, A.; Xu, H.; Oliveira, M.; Hazuda, D.; Wainberg, M. A., Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol., 2010, 84(18), 9210-9216.
130. Goethals, O.; Van Ginderen, M.; Vos, A. M.; Cummings, M. D.; Van der Borght, K.; Van Wesenbeeck, L.; Feyaerts, M.; Verheyen, A.; Smits, V.; Van Loock, M.; Hertogs, K.; Schols, D.; Clayton, R. F., Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res., 2011, 91(2), 167-176.
131. Huang, M.; Grant, G. H.; Richards, W. G., Binding modes of diketo-acid inhibitors of HIV-1 integrase: A comparative molecular dynamics simulation study. J. Mol. Graphics Modell., 2011, 29(7), 956-964.
132. Blanco, J.-L.; Varghese, V.; Rhee, S.-Y.; Gatell, J. M.; Shafer, R. W., HIV-1 integrase inhibitor resistance and its clinical implications. J . Infect. Dis., 2011, 203(9), 1204-1214.
133. (a) Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B. A.; Marchand, D.; Bardiot, D.; Van de Veken, N. J.; Van Remoortel, B.; Strelkov, S. V.; De Maeyer, M.; Chaltin, P.; Debyser, Z., Rational design of small-molecule inhibitors of the LEDGF/p75 - integrase interaction and HIV replication. Nat. Chem. Biol., 2010, 6, 442-448;
134. (b) De Luca, L.; Ferro, S.; Morreale, F.; Chimirri, A., Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: A promising approach in antiretroviral therapy. Rev. Med. Chem., 2011, 11(8), 714-727.